| Patents for A61K 49 - Preparations for testing in vivo (35,376) |
|---|
| 05/04/2006 | WO2006013227A8 Methylamine risks and treatment with n-derivatives of hyperactivity, depression and alcoholism |
| 05/04/2006 | WO2005089398A3 Method for the delivery of sustained release agents |
| 05/04/2006 | WO2005072097A3 Toll-like receptor 9 modulators |
| 05/04/2006 | WO2005065241A3 Smmr (small molecule metabolite reporters) for use as in vivo glucose biosensors |
| 05/04/2006 | WO2005037204A3 Ntrk1 genetic markers associated with age of onset of alzheimer's disease |
| 05/04/2006 | US20060094741 Remedies for neuropathic pain and model animals of neuropathic pain |
| 05/04/2006 | US20060094674 Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms |
| 05/04/2006 | US20060094057 Method for automated, large-scale measurement of the molecular flux rates of the proteome or the organeome using mass spectrometry |
| 05/04/2006 | US20060094014 Nucleic acid supported protein complementation |
| 05/04/2006 | US20060093598 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 05/04/2006 | US20060093587 Transplants for myocardial scars |
| 05/04/2006 | US20060093576 Stabilized liquid polypeptide-containing pharmaceutical compositions |
| 05/04/2006 | US20060093555 Imaging inflammatory conditions using superparamagnetic iron oxide agents |
| 05/04/2006 | US20060093554 Galenical formulations |
| 05/04/2006 | DE102004052533A1 Particles for use in diagnosis and therapy, especially for binding therapeutic agent for treating e.g. tumors and bacterial, rheumatic, neurologic and thrombotic diseases, have nanocrystalline magnetic core and envelope enclosing core |
| 05/04/2006 | DE102004052203A1 Reabsorbable carrier material, useful e.g. in medicinal-technical product and in the human or animal body, comprises silver particles |
| 05/04/2006 | CA2583677A1 Tnf-like weak inducer of apoptosis (tweak) receptor binding domain |
| 05/03/2006 | EP1652533A1 HEART-SLOWING DRUG CONTAINING SHORT-ACTING &bgr; BLOCKER AS THE ACTIVE INGREDIENT |
| 05/03/2006 | EP1651958A1 Novel chemiluminescent compounds and their use |
| 05/03/2006 | EP1651755A2 Method for immunotherapy of tumors |
| 05/03/2006 | EP1651287A2 Injectable composite for the magnetocytolysis of bone metastatic cells |
| 05/03/2006 | EP1651276A1 Emulsion particles for imaging and therapy and methods of use thereof |
| 05/03/2006 | EP1651202A1 Compositions containing prodrugs of florfenicol and methods of use |
| 05/03/2006 | EP1651189A1 Novel metaxalone compositions |
| 05/03/2006 | EP1651097A2 Post-biopsy cavity treatment implants and methods background of the invention |
| 05/03/2006 | EP1363618B1 Pharmaceutical composition for treating multiple sclerosis |
| 05/03/2006 | EP1242060B1 Treatment of metastatic disease |
| 05/03/2006 | EP1087794B8 Light application device for photodynamic diagnosis or photodynamic therapy of diseases of the parodontium and teeth |
| 05/03/2006 | CN1767859A Improved radiometal complex compositions |
| 05/03/2006 | CN1254276C Matrix metalloproteinase inhibitors as targeting components in diagnostic agents |
| 05/02/2006 | US7038106 Detection of neural activity |
| 05/02/2006 | US7037898 Tumor-activated prodrug compounds and treatment |
| 05/02/2006 | US7037510 Hybrids of M. tuberculosis antigens |
| 05/02/2006 | US7037498 Antibodies to insulin-like growth factor I receptor |
| 05/02/2006 | US7036542 Nonskid device for the wheels of vehicles |
| 05/02/2006 | CA2149529C Peptides and anti-sense peptides with broad neoplastic specificity |
| 04/27/2006 | WO2006044856A2 Use of a2a adenosine receptor agonists |
| 04/27/2006 | WO2006044421A2 Cardiac safe, rapid medication delivery |
| 04/27/2006 | WO2006043359A1 Ultrasonic contrast medium |
| 04/27/2006 | WO2006042724A2 Magnetic particles for therapy and diagnosis |
| 04/27/2006 | WO2006009919A3 Improved efficacy of immunotherapy by integrating diagnostic with therapeutic methods |
| 04/27/2006 | WO2005105159A3 Contrast agents for myocardial perfusion imaging |
| 04/27/2006 | WO2005058153A3 Optical imaging contrast agents comprising a targeting vector linked to a fluorophore |
| 04/27/2006 | WO2005020795A3 Method of diagnosis and treatment of pancreatic endocrine neoplasms based on differntial gene expression analysis |
| 04/27/2006 | US20060089320 Modulation of type IIß phosphoinositide phosphate kinase |
| 04/27/2006 | US20060089297 Sperm specific lysozyme-like proteins |
| 04/27/2006 | US20060088827 Diagnostic and therapeutic use of a voltage-gated ion channel scn2a for neurodegenerative diseases |
| 04/27/2006 | US20060088540 Antagonists and methods for inhibiting angiogenesis |
| 04/27/2006 | US20060088521 Composition and method for cancer treatment |
| 04/27/2006 | US20060088476 Loadable polymeric particles for therapeutic and/or diagnostic applications and methods of preparing and using the same |
| 04/27/2006 | US20060088475 Self-immolative magnetic resonance imaging contrast agents sensitive to beta-glucuronidase |
| 04/27/2006 | US20060088474 Endohedral metallofullerene contrast agents |
| 04/27/2006 | US20060088473 Treatment screening methods |
| 04/27/2006 | US20060088472 E7 regulation of p21 cip1 through akt |
| 04/27/2006 | CA2584512A1 Truncated fragments of alpha-synuclein in lewy body disease |
| 04/27/2006 | CA2583185A1 Use of a2a adenosine receptor agonists |
| 04/26/2006 | EP1649746A1 MSH5 ablated mice and uses therefor |
| 04/26/2006 | EP1649263A2 Composite nanoparticles |
| 04/26/2006 | EP1648381A2 Magnetic nanoparticle compositions, and methods related thereto |
| 04/26/2006 | EP1648299A1 Remote detection of substance delivery to cells |
| 04/26/2006 | EP1648224A1 Rat model of diabetic nephropathy |
| 04/26/2006 | EP1648223A1 Npc1l1 (npc3) and methods of use thereof |
| 04/26/2006 | EP1123117B1 Method and apparatus for identifying hyperpolarization state of a gas |
| 04/26/2006 | EP0841949B1 Use of saccharide conjugates |
| 04/25/2006 | US7034934 Anti-carcinogenic lights and lighting |
| 04/25/2006 | US7034201 Developmental animal model of temporal lobe epilepsy |
| 04/25/2006 | US7034183 Using amide of a triiodobenzene compound as chemical intermediate |
| 04/25/2006 | US7034126 Lactoferrin in the treatment of diabetes mellitus |
| 04/25/2006 | US7033841 Quantitative, qualitative analysis; binding measurement; determination magnetism; immunoassay connecting to ferromagnetic substance; magnetization indicators |
| 04/25/2006 | US7033574 Stable microbubbles suspensions injectable into living organisms |
| 04/25/2006 | US7033573 Drawing a small sample of cerebral spinal fluid (CSF), blood and urine; testing for concentrations of glucose and for concentrations of a component of CSF; infusing component of CSF into vein; testing, comparing glucose concentration |
| 04/25/2006 | CA2353520C Animal model for psoriasis for the prevention and treatment of psoriasis in humans |
| 04/20/2006 | WO2006040129A2 Ubiquitin or gamma-crystalline conjugates for use in therapy, diagnosis and chromatography |
| 04/20/2006 | WO2006040125A1 Polymeric contrast agent |
| 04/20/2006 | WO2006020156A3 Heterocyclic dye compounds for in vivo imaging and diagnosis of alzheimer’s disease |
| 04/20/2006 | WO2005120588A3 Peptides delivered to cell nuclei |
| 04/20/2006 | WO2005052125A3 24p3 receptors and uses thereof |
| 04/20/2006 | WO2005017189A3 Neural cell assay |
| 04/20/2006 | US20060084865 Imageable biopsy site marker |
| 04/20/2006 | US20060084701 Diagnosis and treatment of cervical and bladder cancer using hexyl 5-aminolevulinate as a photosensitizer; improved photochemotherapeutic properties; antineoplastic agents |
| 04/20/2006 | US20060083789 Process and system for producing nuclear spin polarized xenon gas |
| 04/20/2006 | US20060083782 Methods and compositions useful for administration of chemotherapeutic agents |
| 04/20/2006 | US20060083745 Cancer treatment kits comprising therapeutic conjugates that bind to aminophospholipids |
| 04/20/2006 | US20060083689 Comprising at least one peptide comprising the amino acid sequence NXEQVSP wherein X is any amino acid, at least one paramagnetic metal ion and at least one chelator |
| 04/20/2006 | US20060083688 Optical determination of glucose utilizing boronic acid adducts |
| 04/20/2006 | US20060083687 Method and system of obtaining improved data in perfusion measurements |
| 04/20/2006 | US20060083686 Therapeutic agent for ulcerative colitis |
| 04/20/2006 | DE3991505B4 Somatostatinpeptide, deren Analoga oder Derivate, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Zusammensetzungen Somatostatin peptides, their analogues or derivatives, to processes for their preparation and pharmaceutical compositions containing them |
| 04/20/2006 | CA2583017A1 Single domain camelide anti-amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenerative neural diseases such as alzheimer's disease |
| 04/19/2006 | EP1647283A1 Polymeric contrast agent |
| 04/19/2006 | EP1646926A2 Characterizing biological stimuli by response curves |
| 04/19/2006 | EP1646856A2 Methods for identifying compounds for regulating muscle mass or function using dopamine receptors |
| 04/19/2006 | EP1646716A1 Yellow fever mosquito deoxyribonucleoside kinases and its use |
| 04/19/2006 | EP1646424A1 Magnetic particles for therapeutic treatment |
| 04/19/2006 | EP1646357A2 Pro104 antibody compositions and methods of use |
| 04/19/2006 | EP1412909A4 System and method for quantitative assessment of joint diseases and the change over time of joint diseases |
| 04/19/2006 | EP1292187B1 Transgenic animal model of neurodegenerative disorders |
| 04/19/2006 | CN1761489A Conjugates for medical imaging comprising carrier, targeting moiety and a contrast agent |
| 04/19/2006 | CN1761484A A method of diagnosis and treatment |
| 04/18/2006 | US7030208 Fluorinated biopolymers and polymers useful in magnetic resonance imaging, diagnostic agents, and contrast agents; for example, polyglutamic acid modified with a perfluoroalkyl epoxide; perfluoroaniline hyaluronate |